Ryan M. Allen

Ryan M. Allen

Auto-generated profile, based on publicly available information

Ryan M. Allen

Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TMTyler J. Marquart
Tyler J. Marquart
RARyan M. Allen
Ryan M. Allen
DODaniel S. Ory
Daniel S. Ory
ÁBÁngel Baldán
Ángel Baldán
The sterol regulatory element binding protein 2 (SREBP-2) and the liver X receptor (LXR) control antagonistic transcriptional programs that stimulate cellular cholesterol uptake and synthesis, and cholesterol efflux, respectively. The clinical importance of SREBP-2 is revealed in patients with hypercholesterolemia treated with statins, which reduce low-density lipoprotein (LDL) cholesterol levels by increasing hepatic expression of SREBP-2 and its target, the LDL receptor. Here we show that miR-33 is encoded within SREBP-2 and that both mRNAs are coexpressed. We also identify sequences in the 3′ UTR of ABCA1 and ABCG1, sterol transporter genes both previously shown to be regulated by LXR, as targets for miR-33–mediated silencing. Our data show that LXR-dependent cholesterol efflux to both ApoAI and serum is ameliorated by miR-33 overexpression and, conversely, stimulated by miR-33 silencing. Finally, we show that ABCA1 mRNA and protein and plasma HDL levels decline after hepatic overexpression of miR-33, whereas they increase after hepatic miR-33 silencing. These results suggest novel ways to manage hypercholesterolemic patients.

1 April 2019 in Cell Reports
Verified
Journal Article
Open access
QZQin Zhang
Qin Zhang
JHJames N. Higginbotham
James N. Higginbotham
DJDennis K. Jeppesen
Dennis K. Jeppesen
YYYu-Ping Yang
Yu-Ping Yang
WLWei Li
Wei Li
RCRobert J. Coffey
Robert J. Coffey
Exomeres are a recently discovered type of extracellular nanoparticle with no known biological function. Herein, we describe a simple ultracentrifugation-based method for separation of exomeres from exosomes. Exomeres are enriched in Argonaute 1-3 and amyloid precursor protein. We identify distinct functions of exomeres mediated by two of their cargo, the β-galactoside α2,6-sialyltransferase 1 (ST6Gal-I) that α2,6- sialylates N-glycans, and the EGFR ligand, amphiregulin (AREG). Functional ST6Gal-I in exomeres can be transferred to cells, resulting in hypersialylation of recipient cell-surface proteins including β1-integrin. AREG-containing exomeres elicit prolonged EGFR and downstream signaling in recipient cells, modulate EGFR trafficking in normal intestinal organoids, and dramatically enhance the growth of colonic tumor organoids. This study provides a simplified method of exomere isolation and demonstrates that exomeres contain and can transfer functional cargo. These findings underscore the heterogeneity of nanoparticles and should accelerate advances in determining the composition and biological functions of exomeres.

1 March 2012 in Cell Cycle
Verified
Journal Article
Closed access
DCDaniel Cirera-Salinas
Daniel Cirera-Salinas
MPMontse Pauta
Montse Pauta
RARyan M. Allen
Ryan M. Allen
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
Cristina M. Ramírez HidalgoCristina M. Ramírez Hidalgo
Cristina M. Ramírez Hidalgo
CFCarlos Fernández-Hernando
Carlos Fernández-Hernando
Cholesterol metabolism is tightly regulated at the cellular level and is essential for cellular growth. microRNAs (miRNAs), a class of noncoding RNAs, have emerged as critical regulators of gene ex...

5 July 2012 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
RARyan M. Allen
Ryan M. Allen
TMTyler J. Marquart
Tyler J. Marquart
CACarolyn J. Albert
Carolyn J. Albert
FSFrederick J. Suchy
Frederick J. Suchy
DWDavid Q.‐H. Wang
David Q.‐H. Wang
ÁBÁngel Baldán
Ángel Baldán
Bile secretion is essential for whole body sterol homeostasis. Loss‐of‐function mutations in specific canalicular transporters in the hepatocyte disrupt bile flow and result in cholestasis. We show that two of these transporters, ABCB11 and ATP8B1, are functional targets of miR‐33, a micro‐RNA that is expressed from within an intron of SREBP‐2. Consequently, manipulation of miR‐33 levels in vivo with adenovirus or with antisense oligonucleotides results in changes in bile secretion and bile recovery from the gallbladder. Using radiolabelled cholesterol, we show that systemic silencing of miR‐33 leads to increased sterols in bile and enhanced reverse cholesterol transport in vivo. Finally, we report that simvastatin causes, in a dose‐dependent manner, profound hepatotoxicity and lethality in mice fed a lithogenic diet. These latter results are reminiscent of the recurrent cholestasis found in some patients prescribed statins. Importantly, pretreatment of mice with anti‐miR‐33 oligonucleotides rescues the hepatotoxic phenotype. Therefore, we conclude that miR‐33 mediates some of the undesired, hepatotoxic effects of statins. →See accompanying article http://dx.doi.org/10.1002/emmm.201201565

18 July 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
LGLeigh Goedeke
Leigh Goedeke
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
Cristina M. Ramírez HidalgoCristina M. Ramírez Hidalgo
Cristina M. Ramírez Hidalgo
LGLiang Guo
Liang Guo
RARyan M Allen
Ryan M Allen
CFCarlos Fernández
Carlos Fernández
Plasma high‐density lipoprotein (HDL) levels show a strong inverse correlation with atherosclerotic vascular disease. Previous studies have demonstrated that antagonism of miR‐33 in vivo increases circulating HDL and reverse cholesterol transport (RCT), thereby reducing the progression and enhancing the regression of atherosclerosis. While the efficacy of short‐term anti‐miR‐33 treatment has been previously studied, the long‐term effect of miR‐33 antagonism in vivo remains to be elucidated. Here, we show that long‐term therapeutic silencing of miR‐33 increases circulating triglyceride (TG) levels and lipid accumulation in the liver. These adverse effects were only found when mice were fed a high‐fat diet (HFD). Mechanistically, we demonstrate that chronic inhibition of miR‐33 increases the expression of genes involved in fatty acid synthesis such as acetyl‐CoA carboxylase (ACC) and fatty acid synthase (FAS) in the livers of mice treated with miR‐33 antisense oligonucleotides. We also report that anti‐miR‐33 therapy enhances the expression of nuclear transcription Y subunit gamma (NFYC), a transcriptional regulator required for DNA binding and full transcriptional activation of SREBP‐responsive genes, including ACC and FAS. Taken together, these results suggest that persistent inhibition of miR‐33 when mice are fed a high‐fat diet (HFD) might cause deleterious effects such as moderate hepatic steatosis and hypertriglyceridemia. These unexpected findings highlight the importance of assessing the effect of chronic inhibition of miR‐33 in non‐human primates before we can translate this therapy to humans.

13 August 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
RARyan M. Allen
Ryan M. Allen
SZShilin Zhao
Shilin Zhao
MSMarisol A. Ramirez Solano
Marisol A. Ramirez Solano
WZWanying Zhu
Wanying Zhu
DMDanielle L. Michell
Danielle L. Michell
KVKasey C. Vickers
Kasey C. Vickers
To comprehensively study extracellular small RNAs (sRNA) by sequencing (sRNA‐seq), we developed a novel pipeline to overcome current limitations in analysis entitled, “Tools for Integrative Genome analysis of Extracellular sRNAs (TIGER)”. To demonstrate the power of this tool, sRNA‐seq was performed on mouse lipoproteins, bile, urine and livers. A key advance for the TIGER pipeline is the ability to analyse both host and non‐host sRNAs at genomic, parent RNA and individual fragment levels. TIGER was able to identify approximately 60% of sRNAs on lipoproteins and >85% of sRNAs in liver, bile and urine, a significant advance compared to existing software. Moreover, TIGER facilitated the comparison of lipoprotein sRNA signatures to disparate sample types at each level using hierarchical clustering, correlations, beta‐dispersions, principal coordinate analysis and permutational multivariate analysis of variance. TIGER analysis was also used to quantify distinct features of exRNAs, including 5ʹ miRNA variants, 3ʹ miRNA non‐templated additions and parent RNA positional coverage. Results suggest that the majority of sRNAs on lipoproteins are non‐host sRNAs derived from bacterial sources in the microbiome and environment, specifically rRNA‐derived sRNAs from Proteobacteria. Collectively, TIGER facilitated novel discoveries of lipoprotein and biofluid sRNAs and has tremendous applicability for the field of extracellular RNA.